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Prevalence and factors associated with disturbed sleep in patients 
with ankylosing spondylitis and non-radiographic axial 
spondyloarthritis: a systematic review 
 
Shaaron Leverment, Emily Clarke, Alison Wadeley, Raj Sengupta 
 
Abstract 
This review explores the prevalence and factors associated with disturbed sleep for patients 
with ankylosing spondylitis and non-radiographic axial spondyloarthritis in order to clarify 
consistent findings in this otherwise disparate research field. The association of physical, 
demographic and psychological factors correlating with poor sleep was explored, and the 
effectiveness of interventions assessed. Ten electronic databases were searched: AMED, 
CINAHL, Embase, Medline, PsycINFO, PubMed, Scopus, Web of Science, OpenGrey and 
BASE. Following application of inclusion and exclusion criteria, 29 articles were critically 
assessed on the basis of methodology, experimental design, ethics and quality of sleep data, 
leading to the selection of 15 studies for final review. Poor sleep was reported in 35–90% 
of patients with axial spondyloarthritis and is more prevalent within this clinical population 
compared to healthy control subjects. Disturbed sleep is an important aspect of disease for 
patients and reflects the severity of disease activity, pain, fatigue and functional disability. 
However, the direction of this relationship is undetermined. Associations with age, gender, 
years spent in education, quality of life and depression have also been demonstrated. Anti-
TNF medication is effective in reducing poor sleep, and exercise has also produced beneficial 
results. Future research into poor sleep should take account of its multifactorial nature. 
There is also a current lack of research investigating nonpharmacological interventions or 
combination therapies. A standardised, validated measurement of poor sleep, appropriate 
for regular patient screening, would be a useful first step for future research. 
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Introduction 
Patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis 
(nraxSpA) share similar burdens of illness in terms of pain, functional impairment, quality of 
life (QoL) and the need for effective treatment [ 1, 2 ]. Pain and stiffness in the axial spine 
impact functional ability and QoL [ 3, 4 ] and patients have associated these symptoms with 
poor sleep [ 5, 6 ]. In an early reference to the problems of sleep in AS, the secretary for the 
National Ankylosing Spondylitis Society wrote, ‘it is at night that the spondylitic feels his 
condition most and is most conscious of the skeletal prison within him’ [ 7 ]. 
 
For patients with early AS, pain and stiffness are thought to be caused by inflammation and 
associated with active disease [ 8 ]. Awakening in the early morning hours may help 
distinguish inflammatory back pain from mechanical low back pain [ 5 ]. Prevalence of 
disturbed sleep is evident in other chronic inflammatory conditions such as psoriatic 
arthritis [ 9, 10 ], rheumatoid arthritis [ 11 ] and inflammatory bowel disease [ 12 ], and 
research suggests that disturbed sleep is associated with active disease, pain, reduced 
physical functioning, demographics and mood within these wider populations [ 13, 14, 15 ]. 
 
Patients with AS prioritise improvement in sleep [ 16 ] and have rated poor sleep as one of 
the most prevalent quality of life concerns [ 17 ]. The impact of poor sleep reaches beyond 
the individual due to associations with fatigue and daytime functioning [ 18 ], and sleep 
disruption resulting from pain, may disrupt full time employment [ 19 ]. 
 
To date, there has been no systematic review investigating the prevalence and modifying 
factors of sleep in AS and nraxSpA patients. The objective of this systematic literature 
review is to make an assessment of our current knowledge in this area, in order to provide a 
focus for future research to improve physical, psychological and social outcomes for 
patients with axial spondyloarthritis (AxSpA). 
 
Methods 
Search strategy 
The following subject-relevant, electronic databases were searched for peer-reviewed, 
primary research articles concerning sleep disturbance within the AxSpA population in 
Page 3 of 27 
 
September 2015: AMED, CINAHL, Embase, Medline, PsycINFO, PubMed, Scopus and Web of 
Science. 
 
The search strategy was a textword search using Boolean logic and did not utilise 
methodologies such as Medical Subject Headings (MeSH) terms. Dates were unrestricted, 
and the following search terms were used: ‘Ankylosing spondylitis’, ‘spondyloarthr*’, 
‘spondylitis’, ‘Strumpell’, ‘Bechterew’ AND ‘sleep’. OpenGrey and BASE were also searched 
for the unpublished, relevant literature in order to limit publication bias. 
 
This review of the current literature adhered to the Preferred Reporting Items for 
Systematic Reviews and MetaAnalyses (PRISMA) [ 20 ] and a PRISMA checklist submitted as 
supplementary material. 
 
Study selection 
As the literature is limited within this field, a total of 101 full text, relevant articles were 
obtained from following this search protocol. Titles, abstracts and, where required, full text 
of all articles were explored and selected according to the criteria stated below: 
 
Inclusion Criteria: 
1. Published literature is peer reviewed. 
2. Grey literature details a process of ethical review. 
3. The article is a primary research study. 
4. Studies which explore sleep disturbance or insomnia as a main area of interest, explored 
using a discrete measure, through qualitative or quantitative analysis and referenced within 
the method or results section of the research paper. 
5. Sleep disruption data specific to patients with a diagnosis of AS or nraxSpA. 
6. The methodology provides clear description of the way in which sleep data are collected. 
 
Exclusion Criteria: 
1. The article is an essay, letter, conference presentation or abstract, review or meta-
analysis. 
2. The article includes secondary analysis of data previously included for review. 
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3. There is no clear distinction between sleep and fatigue data. 
4. The article has no published, full text, English translation. 
 
Any relevant conference reports, posters or abstracts were followed up with an extensive 
online search and direct contact with key authors where possible. This was in order to 
access any unpublished, full text material for inclusion. Although it was beyond the scope of 
this review to obtain unpublished data from the authors of all relevant conference abstracts 
and posters, to our knowledge all existing full text versions of relevant, published papers 
were obtained. Additional snowball search strategies included reference searching for 
relevant published or unpublished literature, but these strategies yielded no further studies 
for inclusion. In total, 29 papers adhered to the inclusion and exclusion criteria (Fig. 1 ). All 
screening against inclusion/exclusion criteria and critical appraisal for included studies were 
independently performed by two authors (SL, ED) with strong inter-rater agreement (κ = 
0.9). Any disagreement in evaluation was resolved through discussion and consensus. 
 
Main outcome variables 
Data collection for each included study followed a template form, in order to extract 
important information such as population characteristics, experimental design and 
methodology, details of intervention, outcome measures, descriptive statistics, analysis and 
findings. In order to examine their validity, reliability, quality and relevance of these articles, 
critical appraisal was based on the CASP checklist tools for RCTs, case control studies, cohort 
and qualitative studies [ 36 ]. 
 
Through the process of applying inclusion and exclusion criteria, which included elements of 
quality assessment, each remaining study was then evaluated on 14 yes/no questions, 
available as supplementary material. 
 
Data extraction and quality assessment was formed independently by 2 authors (SL, ED). 
Studies were first rated on recognised diagnosis of AS and nraxSpA (1 question) and quantity 
and quality of sleep data (2 questions). At this stage, studies were excluded if both 
reviewers independently considered there was a lack of sufficient, focussed and relevant 
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sleep data for inclusion, for example, if data were limited to a single item yes/no outcome 
measure for sleep. 
 
 
 
Fig. 1 Search results detailing number of studies identified, screened, assessed and included 
in final review. 
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Additional questions included: reliability and validation of the instrument used to measure 
sleep disturbance (1 question), experimental study design (4 questions), reported variables 
and independent differences (2 questions), reporting of clinically important outcomes and 
assessment of harmful outcomes (2 questions) and assessment of the reliability and validity 
of conclusions (2 questions). Statements of ethical approval and informed consent were also 
checked. Those studies with the strongest design and greatest relevance to the research 
questions were selected for inclusion. Full details of the checklists utilised for data 
extraction and critical appraisal are available as supplementary material. 
 
Due to these strict selection criteria, it is possible that some trends were lost during critical 
appraisal, for example, the exclusion of papers with minimal, presence/absence data. The 
measures of disturbed sleep utilised within included studies of this review are summarised 
in Table 1 . Data synthesis within this descriptive review is achieved through tabulation and 
narrative structure to draw conclusions and recommendations. 
 
Results 
Demographic data were presented in all 15 studies, and an early age for disease onset for AS 
is evident. Across AS studies (excluding 2 studies incorporating nraxSpA populations [ 27, 34 
] and 1 study reporting median (IQR) data [ 26 ]) the mean population age in years M (SD) = 
36.7 (9.7). The mean disease duration (where reported from age from symptom onset) in 
years M (SD) = 12.3 (7.5). The method of collection of sleep data varied within the 15 studies 
as shown in Table 2 . Two studies included objective measurements of sleep: 
polysomnography (PSG), [ 21, 35 ] and measurement of Apnoea–Hypopnoea Index (AHI) [ 35 
]. Both studies supplemented objective data with subjective data. Therefore, all 15 studies 
included analysis of sleep data collected from subjective questionnaires and reported 
prevalence of sleep disturbance for AS or nraxSpA patients. However, it should be noted 
that the 5 studies that utilised the PSQI sleep scale used a variety of thresholds to determine 
‘poor sleep’, from a PSQI global score ≥5 [ 21 ] to PSQI > 7 [ 29, 32 ]. This is reflected in the % 
of poor sleep reported, with lower PSQI thresholds resulting in a higher % of AS patient 
sample reporting poor sleep quality (Table 2 ). However, healthy control comparisons within 
4 of the 5 PSQI studies support statements that the prevalence of sleep disturbance is 
significantly higher within this clinical group. 
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Table 1 Overview of measures utilised for the collection of sleep data within this review 
Objective 
measures 
 
Name Apnoea–Hypopnoea Index (AHI) 
Description A measure of the number of apnoea (complete cessation of airflow for at least 10 s) 
and hypopnoea (abnormally low respiratory rate or shallow breathing) per hour 
Name Polysomnography (PSG) 
Description Sleep laboratory recording which monitors physical and psychological processes such 
as electroencephalographic, electrooculographic, electromyographic, respiratory 
events, oxygen saturation and leg movements 
Subjective 
measures 
 
Name Ankylosing Spondylitis Quality of Life Index (ASQoL) 
Description 18-item measurement of quality of life for AS patients [ 37 ]. 1 question directly relates 
to sleep Q5 = ‘It’s impossible to sleep’ 
Name Epworth Sleepiness Scale (ESS) 
Description 8-item subjective questionnaire measuring daytime sleepiness, assessing the likelihood 
of falling asleep in everyday situations (for example, sitting reading or stopped at a 
traffic light) [ 38 ] 
Name Jenkins Sleep Evaluation Questionnaire (JSEQ) 
Description 4-item subjective questionnaire measuring frequency and severity of sleep disturbance 
experienced over the past 30 days [ 39 ]. Assesses problems falling asleep, night 
waking, problems staying asleep and feeling tired upon waking after usual amount of 
sleep. The questionnaire relates to the number of nights experiencing problems 
Name Medical Outcomes Study Sleep questionnaire (MOS) 
Description 12-item subjective questionnaire measuring the experience of sleep quality and 
quantity over the past 4 weeks [ 40 ]. 12 items cover 6 domains: ‘Sleep disturbance’ (4 
items—length of time to fall asleep, sleep is restless/tense, trouble falling asleep, 
trouble getting back to sleep), ‘Daytime somnolence’ (3 items—drowsy/sleepy during 
the day, trouble staying awake, napping during the day), ‘Sleep adequacy’ (2 items—
enough sleep to feel rested, get amount of sleep needed), ‘Snoring’ (1 item), 
‘Awakening short of breath or with headache’ (1 item) and ‘Quantity of sleep’ (1 item). 
Each item is rated on a 6-point scale from ‘none of the time’ to ‘all of the time’, except 
for sleep quantity which is measured in hours 
2 MOS Sleep Problem Indexes SPII and SPI-II can be derived from the MOS scale 
SPII is a measure of 6 of the 12 items, and SPI-II is a measure of 9 of the 12 items 
Name The Nottingham Health Profile (NHP) 
Description 2-Part questionnaire to measure the patient’s subjective view of health [ 41 ] 5 
questions in Part I relate to sleep 
Name Pittsburgh Sleep Quality Index (PSQI) 
Description 19 questions measuring sleep disturbance over the past month [ 42 ]. The 7 areas 
covered are: ‘Subjective sleep quality’, ‘Sleep latency’, ‘Seep duration’, ‘Habitual sleep 
efficiency’, ‘Sleep disturbances’, ‘Use of sleep medication’ and ‘Daytime dysfunction’ 
Name Uppsala Sleep Inventory (USI) 
Description 89- item questionnaire measuring sleep and sleep related problems [ 43 ]. Majority of 
questions are on a 5-point scale (range from 1 = ‘no problems’ to 5 = ‘severe problems’ 
or from ‘never occurring’ to ‘very often’). Some questions are yes/no, and 1 question 
utilises qualitative data description 
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Table 2 Summary of study design and sleep data within 15 included studies 
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Abdulaziez 
and Asaad 
[ 21 ] 
Egypt 
Case control, 
Cross-
sectional 
20 n/a 
Sleep laboratory study  
Objective and subjective data 
collected 
PSG + 
PSQI 
Mean total  
PSQI = 8.2 ± 1.5  
PSQI ≥ 5 = poor sleep 
90% of AS sample reported as 
poor sleep quality 
Mean total 
PSQI = 2.4 ± 0.95 
(p < 0.001) 
Altan et al. 
[22] 
Turkey RCT 54 
Balneotherapy 
+ exercise 
Mixed findings for sleep 
improvement at 3 and 24 weeks 
NHP 
(part 1) 
Mean total NHP 
sleep score = 26.0 
No healthy control 
Aydin et al. 
[23] 
Turkey 
Case control, 
Cross-
sectional 
55 n/a  PSQI 
Median total 
PSQI = 7  
PSQI > 5 = poor sleep 
58.1% reported as poor sleep 
quality 
Median total 
PSQI = 5 (med) 
(p < 0.001) 
Bao et al. 
[24] 
China RCT 203 Golimumab 
Significant sleep improvement found 
from baseline to week 14 (p = 0.013) 
and to week 24 (p < 0.001)  
Ongoing improvement for those 
participating to 52 weeks 
JSEQ 
Mean JSEQ score 
(0–20) at baseline 
= 9.5 
No healthy control 
Batmaz et 
al. [25] 
Turkey 
Case control, 
Cross-
sectional 
80 n/a  PSQI 
Mean total 
PSQI = 6.4 ± 3.7 
PSQI > 5 = poor sleep 
50% reported as poor sleep 
quality 
Mean total 
PSQI = 4.6 ± 3 
(p = 0.004) 
Deodhar et 
al. [26] 
Multi-
national 
RCT 356 Golimumab 
Significant sleep improvement with 
treatment at week 14 (p < 0.001). 
 Improvement sustained at week 24 
JSEQ 
Mean JSEQ score 
(0–20) at baseline = 10.6 
No healthy control 
Dougados et 
al. 
[27] 
Multi-
national 
RCT 215 Etanercept 
nr-axSpA 
No statistically significant sleep 
improvement found for MOS SPI 
sleep scores. 
MOS Mean SPI-II = 46.8 
No healthy control 
Population norm 
cited as =25.8 
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Singular difference at week 12 for 
‘sleep quantity’ (p < 0.05) 
Hultgren et 
al. [28] 
Sweden 
Cohort study, 
Cross-
sectional 
70 n/a 
7 participants classified 
as ‘probable AS’ 
Analysed gender differences in detail 
USI 62% reporting too little sleep 
No control but 
utilised community 
based reference 
group report 25% 
Jiang et al. 
[29] 
China 
Cohort study, 
Cross-
sectional 
683 n/a 9.1% aged 12–17 PSQI 
Mean total 
PSQI = 7 ± 4.14 
PSQI > 7 = poor sleep 
37.3% reported as poor sleep 
quality 
No control group 
Karadağ et 
al. [30] 
Turkey 
Case control, 
Cross-
sectional 
171 n/a 
Unusual gender ratio (% 
male = 47.4)  
Individuals on anti-TNF medication 
had no significant difference in sleep 
parameters compared with healthy 
control subjects 
MOS Mean SPI-II = 39.7 ± 197 
Mean SPI- 
II = 34 ± 20.2 
(p = 0.034) 
Karapolat et 
al. 
[31] 
Turkey 
Case control, 
Longitudinal 
38 
Group (I)-
/homebased 
Exercise (II) 
Significant sleep improvements 
found at 6 weeks (p < 0.05) 
NHP 
(part 1) 
Mean total NHP  
sleep score = 27.4 
No healthy control 
Li et al. [32] China 
Case control, 
Cross-
sectional 
314 n/a  PSQI 
Mean total 
PSQI = 6.6 ± 3.6 
PSQI > 7 = poor sleep 35.4% 
reported as poor sleep quality 
Mean total 
PSQI = 5.5 ± 2.51 
(p = 0.02) 
Rudwaleit 
et al. 
[33] 
Multi-
national 
(Europe) 
Cohort, 
Longitudinal 
1135 Adalimumab 
Significant sleep improvements 
found at 6, 12, 20 weeks (p < 0.001) 
MOS + 
‘optimal 
sleep’ 
Mean SPI-II 
= 48.1 ± 19.0 
No control group 
Sieper et al. 
[34] 
Multi-
national  
RCT 325 
Certolizumab 
pegol 
55% AS: 45% nraxSpA 
Significant sleep improvement found 
at week 4 (p < 0.001) and week 24 (p 
< 0.001) 
MOS SPI-
II 
Mean SPI-II = 49.0 No healthy control 
Solak et al. 
[35] 
Turkey 
Cohort, Cross-
sectional 
31 n/a 
Sleep laboratory study 
Objective and subjective data 
collected 
PSG, AHI, 
ESS 
22.6% prevalence of 
OSAS reported 
No control but 
reported 2–7% 
prevalence of OSAS 
in normal 
population 
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Within the 8 descriptive studies that explored associations between total sleep scores and 
patient data, 2 studies lacked data suitable for comparison [ 28, 35 ]. The remaining 6 
studies reported correlating outcomes of the MOS Sleep Problem Index II (SPI-II) and total 
PSQI scales. Correlations reported within these studies as large (≥0.5), medium (≥0.3) and 
small (≥0.1) effect sizes, as rounded to 1 decimal place, are summarised as an illustration in 
Fig. 2 . 
 
 
Fig. 2 An illustration describing the disease-specific, psychological and QoL correlates 
of sleep quality. 
 
 
Sleep quality was reported in 6 descriptive studies, described by total sleep scores from the 
MOS SPI-II [ 30 ] and total PSQI [ 21, 23, 25, 29, 32 ]. Outcome measures include: BASDAI 
Bath Ankylosing Spondylitis Disease Activity Index, Q1 Question 1, BASFI Bath Ankylosing 
Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BASRI 
Bath Ankylosing Spondylitis Radiology Index, BASG Bath Ankylosing Spondylitis Patient 
Global Score, VAS Visual Analogue Scale, ASQoL The Ankylosing Spondylitis Quality of Life 
Scale, FSS Fatigue Severity Scale, BDI Beck’s Depression Inventory, HADSD Hospital Anxiety 
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and Depression Scale for Depression, HADSA Hospital Anxiety and Depression Scale for 
Anxiety, SDS Zung Self-Rating Depression Scale, SAS Zung Self-Rating Anxiety Scale. CRP 
CReactive Protein, ESR Erythrocyte Sedimentation Rate. 
 
Subset questions of the PSQI, MOS and the USI (for example, sleep latency, night 
awakenings, daytime dysfunction) were analysed in greater depth in 5 studies {23, 25, 28, 
30, 32]. Inconsistency between the results, alongside variation in questions that define 
aspects of disturbed sleep, precludes reliable comparisons and conclusions. However, 
consistent trends may emerge with more comparable measurement. Suggested areas for 
exploration include a significantly greater amount of night awakening and disturbance 
during the night for patients with AS compared to control and reference groups in 4 of 5 
studies [ 23, 28, 30, 32 ]. Poorer sleep efficiency, measured by the hours slept/hours spent 
in bed, or the number of hours slept/subjective estimate of need for sleep, was reported by 
AS groups in 4 of 5 studies [ 23, 25, 28, 32 ]. In addition, those studies reporting the use of 
sleep medication found that patients with AS do not appear to use sleep medications 
significantly more than healthy control subjects, despite prevalence of poor sleep [ 23, 25, 
32 ]. Reasons for this are unclear. 
 
Discussion 
Prevalence of sleep disturbance 
On the basis of 15 studies that describe total sleep scores utilising the PSQI, MOS SPI-II, 
JSEQ, USI and NHP (part 1), poor sleep is more prevalent for patients with AxSpA than within 
cited normal populations (Table 2 ). Five studies directly compared overall sleep scores in a 
healthy control group with those in an AS group [ 21, 23, 25, 30, 32 ]. All of these studies 
found significant differences between AS patients and the control subjects. It is likely that 
poor sleep is also more prevalent in patients with nraxSpA that for control subjects, 
however, only 2 studies focussed on this research group [ 27, 34 ]. In comparison between 
nraxSpA and AS patients, patients with nraxSpA reported greater sleep disturbance at 
baseline with greater improvement during treatment with certolizumab pegol [ 34 ]. 
 
Objective data and primary sleep disorders 
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Two laboratory-based studies utilised objective sleep measures (PSG) and support the 
existence of sleep disturbance within the AS population [ 21, 35 ]. Abdulaziez and Asaad [ 21 
] report that patients with AS have a higher % of light sleep (Stage I and II), a lower % of 
deep, slow wave sleep (SWS), and decreased sleep efficiency (total sleep time/time in bed) 
compared with healthy control subjects. The second PSG (cohort) study [ 35 ] reported 
similar mean values for % Stage II sleep (55.4 ± 11.7 compared with 55.1 ± 1.6) and % sleep 
efficiency (75.3 ± 16 compared with 75.1 ± 4.3) [ 35 ]. 
 
Abdulaziez and Asaad [ 21 ] also report that, compared to healthy control subjects, AS 
patients suffer from increased periodic leg movements (PLM). This was reflected by 
Hultgren et al. [ 28 ] who describe high reports of ‘creeping sensation in legs’ (p = 0.0004 for 
female AS patients) and ‘muscular tension’ (p = 0.001). A high incidence of restless leg 
syndrome (RLS) has previously been found in patients with AS [ 44 ] and associated with 
inflammatory and immune changes [ 45 ]. Therefore, reports of PLM and uncomfortable leg 
sensations may be an important aspect of poor sleep within AS. 
 
The presence of obstructive sleep apnoea syndrome (OSAS) for patients was emphasised by 
Solak et al. [ 35 ] with 7 of 31 patients in their cohort meeting their required criteria for 
OSAS and a 40% prevalence of OSAS for patients over 35, compared with 6.3% prevalence 
for patients under 35. Despite a lack of significant findings for increased abnormal apnoea 
and hypopnoea by Abdulaziez and Asaad [ 21 ], the high prevalence of OSAS in patients over 
35 may have important clinical implications. Considering the various possible causative 
associations between AS and OSAS such as impaired mobility, restricted thoracic capacity, 
physiological changes or underlying aetiology [ 46 ], more research is required to replicate 
these findings. 
 
Factors associated with sleep disturbance—demographic variables: age, education and 
gender 
AGE 
Increasing age is correlated with a significant increase in subjective experience of disturbed 
sleep as measured by total PSQI [ 21, 32 ]. Age is also associated with poorer improvement 
on MOS SPI-II during intervention assessment [ 33 ]. However, this does not necessarily 
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relate to disease duration, which was only found to have a significant relationship with 
overall sleep scores in one of these studies [ 21 ]. In addition, it is important to consider that 
sleep naturally changes through life, for example, SWS decreases in older age [ 47 ]. 
 
EDUCATION 
Poor sleep quality had an inverse relationship with the number of years in education [ 33 ], 
with years of education emerging as a significant contributor to sleep disturbance during 
hierarchical multiple regression (p = 0.011) [ 32 ]. A reflection of this may carry through to 
working life, with correlations of poor sleep with increased work time missed and work 
impairment [ 33 ]. 
 
GENDER 
Relationships between total sleep scores and age, disease duration, education and gender 
were not explored in the majority of studies. However, Hultgren et al. [ 28 ] focussed on 
gender differences in explanation of disturbed sleep. In their study of 70 AS patients, 81% of 
female patients reported they were not getting enough sleep, compared to 50% of male 
patients. Female patients also suffered more with night time insomnia and were twice as 
likely to experience pain at bedtime, pain at night and fatigue.  
 
Gender differences were either not found [ 23 ] or not reported [ 21, 25, 30, 32 ] in other 
descriptive studies within this review. In addition, some larger sample studies not included 
in this review do not support a marked gender difference in sleep disruption for AS 
populations [ 16, 17 ]. However, sleep disturbance has been reported as greater for females 
in a large study of 8676 patients with rheumatoid arthritis [ 13 ]. In a study of 47,700 
households, prevalence for insomnia was higher in women and also linked with increased 
age, less education, chronic pain and various comorbidities, many of which are associated 
with inflammation such as osteoporosis, rheumatoid arthritis, depression, ankylosing 
spondylitis and stroke [ 48, 49 ]. 
 
A recent study of fatigue in SpA patients found marked associations with gender [ 50 ], and 
there is mounting evidence to suggest that the experience of rheumatologic disease varies 
between women and men [ 51 ], so it will be of great interest for future research to explore 
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whether demographic trends hinted at within this review can be replicated. They may not 
only point towards variation in subjective experience, but towards differences in underlying 
mechanical manifestation of the disease. 
 
Medical variables: disease activity, function, pain, stiffness and fatigue 
DISEASE ACTIVITY 
When investigating trends in subjective measures, few conclusions can be drawn from single 
reported measures. Figure 2 describes the strong relationships found between increased 
BASDAI and poor sleep scores across 6 comparable studies. All 6 studies report this 
relationship as statistically significant at p < 0.01. PSG data support subjective correlations 
between BASDAI and disturbed sleep [ 21 ]. This mirrors findings for patients with 
rheumatoid arthritis, where prevalent sleep disturbance was significantly associated with 
disease activity [ 11 ]. 
 
Despite this striking association, only 2 of 4 papers that investigating correlations between 
total sleep scores and (CRP/ESR) inflammatory blood markers [ 23, 25, 30, 32 ] reported 
significant correlations [ 23, 32 ] and in only one study was the effect size classified as 
medium strength. This may be due to the questionable validity of ESR/CRP to accurately 
reflect disease activity within this population [ 52 ]. 
 
FATIGUE 
Abdulaziez and Asaad [ 21 ] report highly significant correlations between fatigue and all 
PSG measures. This finding is reflected in a strong correlation (p < 0.001) between total 
sleep scores and fatigue (as measured with the first question of the BASDAI) in two further 
selected studies [ 23, 33 ]. Fatigue has been highlighted in external studies as a major 
symptom associated with AS, with high disease activity predicting high levels of fatigue [ 53 
]. Further studies also support the hypothesis that fatigue is negatively influenced by sleep 
disorders, associated with poor sleep quality and interrupted sleep for patients with 
spondyloarthritis (SpA) [ 54, 55 ]. It has also been proposed that sleep deprivation or chronic 
insomnia may cause shifts in cytokine secretion which then mediate inflammation and play 
a role in the experience of daytime fatigue [ 56, 57 ]. 
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FUNCTIONAL ABILITY 
This review shows a likely, important interrelationship between increased disturbed sleep 
and lower functional ability [ 21, 23, 29, 32 ]. All these studies utilised the PSQI scale which 
showed significant correlations at p < 0.01. Batmaz et al. [ 25 ] found no significant 
relationships between total sleep scores and BASFI but, alongside Abdulaziez and Asaad [ 21 
], they did discover a relationship between poor sleep and decreased mobility as measured 
by the BASMI [ 21, 25 ]. 
 
PAIN 
Pain was measured by a separate VAS in three descriptive studies [ 21, 25, 32 ] and 
positively correlated with higher total PSQI in all 3. In two of these studies, pain also 
remained an important independent factor that significantly contributes to total sleep 
scores during multiple regression analysis [ 25, 32 ]. Pain also correlated with increased % 
Stage I sleep, increased movement at night and decreased % SWS [ 21 ]. It also has strong 
association with increased use of sleep medication [ 25, 32 ]. 
 
Patients’ report shows pain as an important factor in disturbed sleep. In a sample of 43 AS 
patients who reported sleep disturbance, 36% stated that pain was the most important 
factor [ 28 ]. Pain at bedtime, during the pre-sleep period and during the night, was a major 
problem both for men and women in this study, associated with night awakenings and 
increased movement at night (p < 0.0001). Decreased night pain was also the most 
significant predictor of improvement in observed JSEQ scores in an intervention study by 
Deodhar et al. [ 26 ]. However, this relationship is not clear, for example, a highly significant 
improvement in night pain with balneotherapy and exercise was not always accompanied by 
significant improvement in sleep [ 22 ]. 
 
Wider research suggests a reciprocal relationship between the subjective experience of 
chronic pain and disturbed sleep [ 58 ] with some evidence suggesting that sleep deprivation 
can even reduce the analgesic effects of pharmacological treatment [ 59 ]. As pain is known 
to affect fatigue, psychological distress, QOL and ability to work [ 60 ], AxSpA patients would 
benefit from a greater understanding of the role that refreshing sleep may play in the 
management of pain [ 61 ]. 
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Psychological variables: quality of life, depression and anxiety 
Psychological factors such as mood have been shown to contribute to sleep disturbance in 
rheumatoid arthritis [ 13 ] and in a mixed SpA population [ 15 ]. This review also showed 
that psychological factors such as depression, anxiety and overall QoL are associated with 
poor sleep quality for patients with AxSpA [ 21, 25, 32 ]. QoL as measured by the ASQoL was 
utilised in two studies [ 21, 25 ], both of which found a significant relationship between 
disturbed sleep and reduced ASQoL score. However, it should be noted that the ASQoL 
contains a measure of sleep within it. 
 
17% of 43 AS patients reported sociopsychological factors as the most important factor 
affecting disturbed sleep [ 28 ]. Physical and mental components were both significant 
predictors of improvement in JSEQ scores in a drug study investigating golimumab [ 26 ]. 
Depression was investigated in four separate studies [ 21, 25, 28, 32 ] using four different 
measures (including a single question ‘do you have problems with feeling depressed?’ [ 28 
]). Depression had a positive correlation with poor sleep quality in two of these studies (p < 
0.01) [ 25, 32 ], and despite a nonsignificant result reported by Abdulaziez and Asaad [ 21 ] 
(p = 0.173) the effect size is still classified as medium (Fig. 2 ). A recent Korean study of 40 
patients with AS supports a positive association between depression and poor sleep, finding 
that depression as assessed by the BDI, alongside duration of morning stiffness, remained as 
independent risk factors that affected poor sleep (total PSQI) [ 62 ]. Li et al. [ 32 ] also report 
a large and statistically significant association between anxiety and total PSQI sleep score. 
They suggest that psychological variables play an important role and may contribute as 
much as medical variables when assessing disturbed sleep. 
 
Effectiveness of interventions 
MEDICATION 
Seven studies included in this review looked at effectiveness of interventions with sleep 
disturbance as an outcome measure. Five of them investigated anti-TNF therapy, specifically 
golimumab [ 24, 26 ], etanercept [ 27 ], adalimumab [ 33 ] and certolizumab pegol [ 34 ]. 
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Four of the five studies found that anti-TNF medication was effective in reducing overall 
sleep scores, with improvement maintained throughout the trial period [ 24, 26, 33, 34 ]. In 
one study, the median JSEQ further improved to week 52 for those receiving treatment for 
the full year, indicating that individuals may see continued improvement into the long term 
[ 24 ]. Improvements in sleep score from baseline were associated with improved back pain, 
fatigue, QoL, disease activity and functional ability [ 26, 34 ]. One of the descriptive studies 
grouped individuals depending on current use of anti-TNF medication. They found that sleep 
scores for AS patients (MOS scores for sleep disturbance, somnolence, waking with a 
headache or shortness of breath and the Sleep Problem Index II) were significantly worse 
the group taking NSAID and/or DMARDs compared to control subjects. The patients taking 
anti-TNF medication did not differ from control subjects. In this study, the BASDAI and 
BASFI scores were also significantly worse for the NSAID/DMARD group. Therefore, the poor 
sleep scores may be a reflection of the poorer control of disease activity in this group. 
 
In contradiction to this trend, one intervention study reports no statistically significant 
improvement in overall MOS Sleep scores with etanercept intervention [ 27 ]. Two 
descriptive studies [ 23, 25 ] also found no significant correlation between the type of 
medication used to control disease activity (NSAIDS, DMARDS and anti-TNF) and total PSQI, 
despite a large proportion of the patients (20.4% [ 23 ] and 53.8% [ 25 ]) of the patients 
taking anti-TNF medication. However, this review concludes that there is a likely association 
between use of anti-TNF medication and a reduction in disturbed sleep for patients. This is 
supported by growing research into the complex interplay of cytokines, sleep and immunity 
[ 63 ]. 
 
Few studies controlled for other medications which may impact sleep. Amitriptyline, a 
tricyclic antidepressant often used for pain relief, may result in improved sleep and a 
reduction in BASDAI [ 64 ]. Therefore, future studies investigating sleep in AxSpA must 
control medication use, particularly for current and recent use of anti-TNF medication [ 33 ], 
in order to strengthen the validity and reliability of findings. 
 
EXERCISE 
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Few studies have looked at naturalistic or psychological interventions. The two included in 
this review investigate the effects of exercise and used Part 1 of the NHP to assess disturbed 
sleep in AS [ 22, 31 ]. 
 
Altan et al. [ 22 ] found mixed improvement in sleep scores between Group I (balneotherapy 
+ exercise) and Group II (exercise only). For Group I, a significant improvement in sleep 
found at 3 weeks was not maintained at 24 weeks, with NHP sleep scores recorded at 18.30 
± 28.26 at week 0 and 18.60 ± 29.98 at week 24. Conversely with Group II, the improvement 
was not significant at 3 weeks, but highly significant 24 weeks (p < 0.001). Outcome 
measures such as night pain and disease activity had a more significant and more sustained 
improvement over 24 weeks with the intervention than improved sleep [ 22 ]. The second 
study [ 31 ] investigated homebased and group-based exercise and found significant 
improvement in sleep scores of the NHP in both groups with a statistically significant 
greater, between-group improvement for sleep scores in favour of group-based exercise. 
 
Regular exercise is already emphasised as an important aspect of the long-term 
management of AS [ 1 ] and has been shown to have an analgesic effect [ 65 ] which may 
help AS patients cope with pain. Masiero et al. [ 66 ] found that exercise, in combination 
with an educational–behavioural program and anti-TNF therapy, had a greater effect on 
symptoms of disease activity in AS patients than either intervention used alone. Within the 
2 studies of this review, regular exercise also saw benefits in BASDAI, BASFI, BASMI, morning 
stiffness, pain, energy and emotional reaction [ 22, 31 ]. Further research is required to 
clarify the possible mediating effects of exercise on improving poor sleep. 
 
Increased recognition and a validated measure for poor sleep 
Many studies call for raised awareness of disturbed sleep by clinicians [ 21, 23, 25, 29 ]. 
Screening for sleep problems during patient assessment will benefit those who consider 
sleep disturbance as a primary concern that impacts QoL [ 17, 28, 67 ] as well as identifying 
primary sleep disorders that may require treatment. 
 
However, there is currently no validated sleep measure for this clinical population. A variety 
of sleep-relevant scales are used within papers investigating sleep (Table 1 ), but 
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inconsistencies in the choice of sleep scales and methods for determining ‘poor sleep’ 
across studies obscured conclusions that could have be drawn. A standard, efficient, easily 
administered questionnaire that clearly distinguishes fatigue and disturbed sleep would be a 
useful first step for future research. Incorporation of a question that utilises qualitative data 
may provide important insights. For example, a qualitative question on the USI used by 
Hultgren et al. [ 28 ] enabled the researchers to discover that 9% of the 43 patients who 
reported sleep disturbance were waking in the night for reasons unrelated to disease, such 
as being woken by children or snoring. In addition, a new questionnaire should report on 
normal sleeping habits. Many individuals have a natural sleep pattern, free from disease, 
that involves night time awakenings or initial insomnia. Finally, the option of the inclusion of 
objectively observed data from a bed partner or from wearable sleep-monitoring devices 
could provide valuable supplementary data which may be particularly useful when assessing 
the presence of apnoea and hypopnoea. 
 
Limitations 
The majority of studies investigating sleep disturbance as the primary focus are a cross-
sectional design utilising questionnaires which reveal close correlations in subjective scoring 
for symptoms such as disease activity, pain, fatigue and sleep. Greater consideration of 
longitudinal design would provide some control for individual differences which may 
contribute to these strong correlations. 
 
It is also noted that, during longitudinal intervention studies, improvement was greatest for 
individuals with more severe AS symptoms at baseline, for example, BASDAI [ 33 ] or sleep 
scores [ 34 ]. This is an important consideration for highly significant improvements in 
studies where participants are specifically recruited with a high BASDAI at baseline. 
 
It also should be noted that a lack of significant findings in sleep disturbance between 
control subjects and AS subjects may not reflect an absence of that sleep disorder. Studies 
within this review found a measure of sleep disturbance within the general population [ 23, 
28 ]. For example, 1 in 10 individuals from a large population reference group had consulted 
a doctor for sleep disturbance [ 28 ]. This may call into question whether the insignificant 
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finding of use of sleep medication is more reflective of a prevalence within the general 
population. 
 
Conclusions 
This review highlights disturbed sleep as a significant problem within this population that 
requires more extensive evaluation. Disturbed sleep is a multifactorial, prevalent and 
important aspect of disease that concerns patients with AxSpA. There are associations 
between poor sleep quality and disease activity, function, fatigue, pain and QoL. It is 
probable that demographic aspects (including gender, age and education) alongside 
psychological factors, such as depression, play a role in disturbed sleep. The direction of 
these relationships, or whether disturbed sleep is driven by common, underlying processes, 
is unclear. Research has shown both that activation of the immune system disturbs sleep [ 
56, 68 ] and that abnormal sleep can disrupt immune system function [ 69, 70 ]. Future 
research may shed light on these complex relationships. There is some evidence from 
patients to suggest that sleep provides relief from disease flares [ 71 ]. Whether treatments 
that target sleep disturbance can affect disease activity, pain, function or severity of fatigue 
remains to be seen. 
 
Interventions such as anti-TNF medication and regular exercise are associated with a 
reduction in sleep problems. However, there are very few studies investigating 
nonpharmacological interventions. Recognition of the physical, psychological and 
sociological influences associated with sleep can lead to the development of more holistic 
interventions that target the many facets of disturbed sleep through a combination of 
therapies. Full consideration of the use of current medication and exercise habits is 
important in order to allow more rigorous and practical conclusions to be drawn in future 
research. 
 
Abnormal sleep may exacerbate chronic inflammatory conditions [ 72 ]. It has also been 
proposed that management of poor sleep could be a non-invasive method to evaluate 
subclinical inflammation and may even play a role in keeping disease in remission [ 13 ]. 
Whether sleep disruption could act as an early warning flag, due to association of underlying 
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inflammation, is a further interesting step for investigation. The presence of abnormal sleep 
for patients with Crohn’s disease in remission at baseline has been linked with 2× increased 
risk of disease flare within the subsequent 6 months [ 14 ]. Two separate longitudinal 
studies found that individuals with sleep disorder [ 73 ] and patients with obstructive sleep 
apnoea [ 74 ] were at a higher risk for developing autoimmune diseases (including 
ankylosing spondylitis). It is therefore possible that regular screening for disturbed sleep 
could be useful in assessing disease activity and predicting future flares. Considering the 
close correlations between poor sleep and the signs and symptoms of active disease, a 
combination of pharmacological, psychological and naturalistic interventions targeted at 
disturbed sleep may break a cycle that aggravates inflammation, thus reducing disease 
impact and improving quality of life for those who suffer with AxSpA. 
 
Acknowledgements 
We would like to offer a special acknowledgement to the following for support of their time 
and expertise during the research and writing of this project: Dr. Alison Lee, Coordinator of 
Graduate Studies in Psychology; Dr Robert Irwin, Senior Lecturer at Bath Spa University; 
Charles Jenkins, Producer at BBC Bristol. 
 
Compliance with ethical standards 
 
Conflict of interest Shaaron Leverment declares that she has no conflict of interest. Alison 
Wadeley declares that she has no conflict of interest. Emily Clarke declares that she has no 
conflict of interest. Dr. Raj Sengupta has received research grants from Abbvie and Pfizer, 
speaker honoraria from Abbvie, Pfizer, UCB, Novartis, Roche, MSD and is a member of BSR 
Biologics guideline group, Advisor to NICE Guideline TA383. 
Ethical standard All procedures performed in studies involving human participants were in 
accordance with the ethical standards of the institutional and/or national research 
committee and with the 1964 Helsinki Declaration and its later amendments or comparable 
ethical standards. 
Human and animal rights This article does not contain any studies with animals performed 
by any of the authors. 
 
Page 22 of 27 
 
References 
 
1. Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, Krause D, Schmitzbortz 
E, Flörecke M, Bollow M, Braun J (2012) Do patients with non-radiographic axial 
spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res 64:1415–
1422 
 
2. Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak 
S (2015) The burden of nonradiographic axial spondyloarthropathy. Semin Arthritis Rheum 
44:556–562 
 
3. Dalyan M, Güner A, Tuncer S, Bilgiç A, Arasil T (1999) Disability in ankylosing spondylitis. 
Disabil Rehabil 21:74–79 
 
4. Bostan E, Borman P, Bodur H, Barca N (2003) Functional disability and quality of life in 
patients with ankylosing spondylitis. Rheumatol Int 23:121– 126 
 
5. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J (2006) Inflammatory back pain in 
ankylosing spondylitis: a reassessment of the clinical history for application as classification 
and diagnostic criteria. Arthritis Rheum 54:569–578 
 
6. Hart F, Taylor R, Huskisson E (1970) Pain at night. Lancet 295:881–884 
 
7. Tanfield M (1978) Ankylosing spondylitis and sleep. Lancet 311:944–945 
 
8. Sengupta R, Stone MA (2007) The assessment of ankylosing spondylitis in clinical practice. 
Nat Clin Pract Rheumatol 3:496–503 
 
9. Callis Duffin K, Wong B, Horn EJ, Krueger GG (2009) Psoriatic arthritis is a strong predictor 
of sleep interference in patients with psoriasis. J Am Acad Dermatol 60:604–608 
 
10. Duruöz MT, Sari Sürmeli Z, Uçar Ü, Topçu E, Duruöz E (2013) Evaluation of sleep quality 
in psoriatic arthritis patients. Ann Rheum Dis 72:A682 
 
11. Taylor-Gjevre R, Gjevre JA, Skomro R, Nair BV (2011) Assessment of sleep health in 
patients with rheumatic disease. Int J Clin Rheumatol 6:207– 218 
 
12. Kinnucan JA, Rubin DT, Ali T (2013) Sleep and inflammatory bowel disease: exploring the 
relationship between sleep disturbances and inflammation. Gastroenterol Hepatol 9:718–
727 
 
13. Wolfe F, Michaud K, Li T (2006) Sleep disturbance in patients with rheumatoid arthritis: 
evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 33:1942–
1951 
 
Page 23 of 27 
 
14. Ananthakrishnan AN, Long MD, Martin CF, Sandler RS, Kappelman MD (2013) Sleep 
disturbance and risk of active disease in patients with Crohn’s disease and ulcerative colitis. 
Clin Gastroenterol Hepatol 1:965–971 
 
15. Da Costa D, Zummer M, Fitzcharles MA (2009) Determinants of sleep problems in 
patients with spondyloarthropathy. Musculoskelet Care 7:143–161 
 
16. Heiberg T, Lie E, van Der Heijde D, Kvien TK (2011) Sleep problems are of higher priority 
for improvement for patients with ankylosing spondylitis than for patients with other 
inflammatory arthropathies. Ann Rheum Dis 70:872 
 
17. Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 
patients. Arthritis Care Res 12:247–255 
 
18. Eilertsen G, Ormstad H, Kirkevold M, Mengshoel A, Söderberg S, Olsson M (2015) 
Similarities and differences in the experience of fatigue among people living with 
fibromyalgia, multiple sclerosis, ankylosing spondylitis and stroke. J Clin Nurs 24:2023–2034 
 
19. Deshpande K, Wininger K (2009) Spinal cord stimulation for pain management in 
ankylosing spondylitis: a case report. Neuromodulation 12:54–59 
 
20. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group: preferred reporting 
items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 
151:264–269 
 
21. Abdulaziez O, Asaad T (2012) Sleep problems in ankylosing spondylitis: 
polysomnographic pattern and disease related variables. Egypt Rheumatol 34:59–65 
 
22. Altan L, Bingöl U, Aslan M, Yurtkuran M (2006) The effect of balneotherapy on patients 
with ankylosing spondylitis. Scand J Rheumatol 35:283–289 
 
23. Aydin E, Bayraktar K, Turan Y, Kurt Omurlu I, Tastaban E, Sendur O (2015) Sleep quality 
in patients with ankylosing spondylitis. Rev Bras Reumatol 55:340–345 
 
24. Bao C, Huang F, Khan M, Fei K, Wu Z, Zhuang Y, Gathany T, Han C, Hsia E (2014) Safety 
and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1year 
results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. 
Rheumatol 53:1654–1663 
 
25. Batmaz I, Sariyildiz M, Dilek B, Bez Y, Karakoc M, Cevik R (2013) Sleep quality and 
associated factors in ankylosing spondylitis: relationship with disease parameters, 
psychological status and quality of life. Rheumatol Int 33:1039–1045 
 
26. Deodhar A, Braun J, Inman R, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, 
van der Heijde D (2010) Golimumab reduces sleep disturbance in patients with active 
ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Care 
Res 62:1266–1271 
Page 24 of 27 
 
 
27. Dougados M, Tsai WC, Saaibi DL, Bonin R, Bukowski J, Pedersen R, Vlahos B, Kotak S 
(2015) Evaluation of health outcomes with etanercept treatment in patients with early non-
radiographic axial spondyloarthritis. J Rheumatol 42:1835–1841 
 
28. Hultgren S, Broman J, Gudbjörnsson B, Hetta J, Lindqvist U (2000) Sleep disturbances in 
outpatients with ankylosing spondylitis a questionnaire study with gender implications. 
Scand J Rheumatol 29:365–369 
 
29. Jiang Y, Yang M, Wu H, Song H, Zhan F, Liu S, Gao G, Liu Z, Hu Z, He P, Zhang S, Hu Z, Lin 
Z, Zhang Y, Li Y, Shen L, Huang A, Liao Z, Cao S, Wei Y, Li L, Li Q, Lv Q, Qi J, Huang J, Li T, Jin O, 
Pan Y (2015) The relationship between disease activity measured by the BASDAI and 
psychological status, stressful life events, and sleep quality in ankylosing spondylitis. Clin 
Rheumatol 34:503–510 
 
30. Karadağ O, Nakas D, Kalyoncu U, Akdoğan A, Kiraz S, Ertenli I (2012) Effect of anti-TNF 
treatment on sleep problems in ankylosing spondylitis. Rheumatol Int 32:1909–1913 
 
31. Karapolat H, Akkoc Y, Sari I, Eyigor S, Akar S, Kirazli Y, Akkoc N (2008) Comparison of 
group-based exercise versus home-based exercise in patients with ankylosing spondylitis: 
effects on Bath Ankylosing Spondylitis Indices, quality of life and depression. Clin Rheumatol 
27:695–700 
 
32. Li Y, Zhang S, Zhu J, Du X, Huang F (2012) Sleep disturbances are associated with 
increased pain, disease activity, depression, and anxiety in ankylosing spondylitis: a case-
control study. Arthritis Res Ther 14:R215 
 
33. Rudwaleit M, Gooch K, Michel B, Herold M, Thörner A, Wong R, Kron M, Chen N, Kupper 
H (2011) Adalimumab improves sleep and sleep quality in patients with active ankylosing 
spondylitis. J Rheumatol 38:79–86 
 
34. Sieper J, Kivitz A, Van Tubergen A, Deodhar A, Coteur G, Woltering F, Landewe R (2015) 
Impact of certolizumab pegol on patient-reported outcomes in patients with axial 
spondyloarthritis. Arthritis Care Res 67:1475–1480 
 
35. Solak Ö, Fidan F, Dündar Ü, Türel A, Ayçiçek A, Kavuncu V, Unlü M (2009) The prevalence 
of obstructive sleep apnoea syndrome in ankylosing spondylitis patients. Rheumatol 
48:433–435 
 
36. Critical Appraisal Skills Programme (2014) CASP checklists. CASP, Oxford. 
http://www.casp.uk/net. Accessed 8 Oct 2015 
 
37. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, McKenna SP, 
Tennant A, van der Heijde D, Chamberlain MA (2003) The development of the ASQOL: a 
quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62:20–26 
 
Page 25 of 27 
 
38. Johns MW (1991) A new method for measuring daytime sleepiness: the Epworth 
sleepiness scale. Sleep 14:540–545 
 
39. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM (1988) A scale for the estimation of sleep 
problems in clinical research. J Clin Epidemiol 41:313–321 
 
40. Hays R, Stewart A (1992) Sleep measures. In: Ware JE Jr, Sherbourne CD (1992) The MOS 
36-item short-form health survey (SF36): I. Conceptual framework and item selection. Med 
Care 30 (6): 473–483 
 
41. Hunt S, McEwan J, McKenna S (1985) Measuring health status: a new tool for clinicians 
and epidemiologists. J R Coll Gen Pract 35 (273):185–188 
 
42. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh Sleep 
Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 
28:193–213 
 
43. Hetta J, Almqvist M, Ågren H, Hambert G, Liljenberg B, Roos BE (1985) Prevalence of 
sleep disturbances and related symptoms in a middle-aged Swedish population. In: Koella 
WP, Ruther E, Schulz H (eds) Sleep ‘84. Gustav Fischer Verlag, Stuttgart, pp 373–376 
 
44. Tekatas A, Pamuk ON (2015) Increased frequency of restless leg syndrome in patients 
with ankylosing spondylitis. Int J Rheum Dis 18:58–62 
 
45. Weinstock LB, Walters AS, Paueksakon P (2012) Restless legs syndrome —theoretical 
roles of inflammatory and immune mechanisms. Sleep Med Rev 6:341–354 
 
46. Yamamoto J, Okamoto Y, Shibuya E, Nishimura M, Kawakami Y (2000) Obstructive sleep 
apnea syndrome induced by ossification of the anterior longitudinal ligament with 
ankylosing spondylitis. Nihon Kokyuki Gakkai Zasshi 38:413–416 
 
47. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV (2004) Metaanalysis of 
quantitative sleep parameters from childhood to old age in healthy individuals: developing 
normative sleep values across the human lifespan. Sleep 27:1255–1273 
 
48. Sivertsen B, Krokstad S, Øverland S, Mykletun A (2009) The epidemiology of insomnia: 
associations with physical and mental health. The HUNT2 study. J Psychosom Res 67:109–
116 
 
49. Sivertsen B, Lallukka T, Salo P, Pallesen S, Hysing M, Krokstad S, Øverland S (2014) 
Insomnia as a risk factor for ill health: results from the large population-based prospective 
HUNT Study in Norway 2014. J Sleep Res 23:124–132 
 
50. López-Medina C, Schiotis RE, Font-Ugalde P, Castro-Villegas MC, Calvo-Gutiérrez J, 
Ortega-Castro R, Jiménez-Gasco R, Escudero-Contreras A, Collantes-Estévez E (2016) 
Assessment of fatigue in spondyloarthritis and its association with disease activity. J 
Rheumatol 43:751–757 
Page 26 of 27 
 
 
51. Abad V, Guilleminault C (2014) Sleep deprivation and rheumatologic disease. Sleep 
deprivation and disease: effects on the body, brain and behavior. Springer, New York, pp 
149–170 
 
52. Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and Creactive 
protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966–970 
 
53. Günaydin R, Göksel Karatepe A, Ceşmeli N, Kaya T (2009) Fatigue in patients with 
ankylosing spondylitis: relationships with disease-specific variables, depression, and sleep 
disturbance. Clin Rheumatol 28:1045–1051 
 
54. Da Costa D, Zummer M, Fitzcharles M (2011) Biopsychosocial determinants of physical 
and mental fatigue in patients with spondyloarthropathy. Rhematol Int 31(4):473–480 
 
55. Missaoui B, Revel M (2006) Fatigue in ankylosing spondylitis. Ann Readapt Med Phys 
49:389–391 
 
56. SpathSchwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, Fehm HL, 
Born J (1998) Acute effects of recombinant human interleukin6 on endocrine and central 
nervous sleep functions in healthy men. J Clin Endocrinol Metab 83:1573–1579 
 
57. Vgontzas A, Zoumakis M, Papanicolaou D, Bixler E, Prolo P, Lin HM, VelaBueno A, Kales 
A, Chrousos GP (2002) Chronic insomnia is associated with a shift of interleukin-6 and tumor 
necrosis factor secretion from night-time to daytime. Metabolism 51:887–892 
 
58. Smith MT, Haythornthwaite JA (2004) How do sleep disturbance and chronic pain 
interrelate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. 
Sleep Med Rev 8:119–132 
 
59. Kundermann B, Krieg JC, Schreiber W, Lautenbacher S (2004) The effect of sleep 
deprivation on pain. Pain Res Manag 9:25–32 
 
60. Moore AR (2013) What works for whom? Determining the efficacy and harm of 
treatments for pain. Pain 154:S77–S86 
 
61. Moldofsky H (2001) Sleep and pain. Sleep Med Rev 5:387–398 
 
62. Jeong HJ, Lee TH, Lee JM, Choi G, Son CN, Kim JM, Cho YW, Kim SH (2014) Sleep 
disturbances in Korean patients with ankylosing spondylitis are associated with increased 
disease activity. J Rheum Dis 21:241–247 
 
63. Irwin M (2002) Effects of sleep and sleep loss on immunity and cytokines. Brain Behav 
Immunol 16:503–512 
 
Page 27 of 27 
 
64. Koh WH, Pande I, Samuels A, Jones SD, Calin A (1997) Low dose amitriptyline in 
ankylosing spondylitis: a short term, double blind, placebo controlled study. J Rheumatol 
24(11):2158–2161 
 
65. Koltyn KF (2000) Analgesia following exercise. A review. Sports Med 29:85–98 
 
66. Masiero S, Bonaldo L, Pigatto M, Nigro AL, Ramonda R, Punzi L (2011) Rehabilitation 
treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor 
inhibitor therapy. A randomized controlled trial. J Rheumatol 38(7):1335–1342 
 
67. Mease P, Rao S, Joshi A, Clifford S, Vernon C, Cifaldi M (2013) Quality of life, physical 
function and symptoms in non-radiographic axial spondyloarthritis: The patient perspective. 
Arthritis Rheumatol 65:S1053 
 
68. Takahashi S, Kapas L, Fang J, Krueger JM (1999) Somnogenic relationships between 
tumor necrosis factor and interleukin-1. Am J Physiol 276(4):R1132–R1140 
 
69. Born J, Lange T, Hansen K, Molle M, Fehm HL (1997) Effects of sleep and circadian 
rhythm on human circulating immune cells. J Immunol 158:4454–4464 
 
70. Everson CA (1993) Sustained sleep deprivation impairs host defense. Am J Physiol 
265(5):R1148–R1154 
 
71. Brophy S, Calin A (2002) Definition of disease flare in ankylosing spondylitis: the patients’ 
perspective. J Rheumatol 29:954–958 
 
72. Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A (2007) The relevance of 
sleep abnormalities to chronic inflammatory conditions. Inflamm Res 56:51–57 
 
73. Hsiao Y, Chen Y, Tseng C, Wu L, Lin W, Su V, Perng D, Chang S, Chen Y, Chen T, Lee Y, 
Chou K (2015) Sleep disorders and increased risk of autoimmune diseases in individuals 
without sleep apnea. Sleep 38:581–586 
 
74. Kang J, Lin H (2012) Obstructive sleep apnea and the risk of autoimmune diseases: a 
longitudinal population based study. Sleep Med 13:583–588 
